Company’s 36-month beta value is 0.88.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ESPR is 168.54M, and currently, short sellers hold a 11.04% ratio of that floaft. The average trading volume of ESPR on April 30, 2024 was 6.23M shares.
ESPR) stock’s latest price update
The stock price of Esperion Therapeutics Inc. (NASDAQ: ESPR) has surged by 4.74 when compared to previous closing price of 1.90, but the company has seen a 4.19% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-29 that ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.
ESPR’s Market Performance
ESPR’s stock has risen by 4.19% in the past week, with a monthly drop of -25.75% and a quarterly drop of -8.29%. The volatility ratio for the week is 7.57% while the volatility levels for the last 30 days are 11.21% for Esperion Therapeutics Inc. The simple moving average for the last 20 days is -16.13% for ESPR stock, with a simple moving average of 11.26% for the last 200 days.
ESPR Trading at -17.14% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.47% of loss for the given period.
Volatility was left at 11.21%, however, over the last 30 days, the volatility rate increased by 7.57%, as shares sank -28.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.19% lower at present.
During the last 5 trading sessions, ESPR rose by +4.19%, which changed the moving average for the period of 200-days by +31.79% in comparison to the 20-day moving average, which settled at $2.3328. In addition, Esperion Therapeutics Inc. saw -33.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who sale 742 shares at the price of $1.25 back on Sep 20 ’23. After this action, Warren Eric now owns 68,318 shares of Esperion Therapeutics Inc., valued at $924 using the latest closing price.
Warren Eric, the Chief Commercial Officer of Esperion Therapeutics Inc., sale 243 shares at $1.41 during a trade that took place back on Aug 18 ’23, which means that Warren Eric is holding 69,060 shares at $344 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- -1.34 for the present operating margin
- 0.63 for the gross margin
The net margin for Esperion Therapeutics Inc. stands at -2.04. The total capital return value is set at -3.14.
Based on Esperion Therapeutics Inc. (ESPR), the company’s capital structure generated 6.49 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at -1.18. The interest coverage ratio of the stock is 1767.76.
Currently, EBITDA for the company is -155.4 million with net debt to EBITDA at -2.97. When we switch over and look at the enterprise to sales, we see a ratio of 6.86. The receivables turnover for the company is 2.4for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.29.
Conclusion
In a nutshell, Esperion Therapeutics Inc. (ESPR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
